60 Degrees Pharmaceuticals to present data on tafenoquine antimalarial regimen

60 Degrees Pharmaceuticals will present a poster titled, “Long-term safety of the tafenoquine antimalarial chemoprophylaxis regimen, a 12-month, randomized double-blind placebo-controlled trial” at the International Lyme & Associated Diseases Society annual conference in Boston on October 21, 2023. The poster will be presented by 60 Degrees Pharmaceuticals Chief Executive Officer, Geoff Dow, PhD. Tafenoquine is approved for malaria prophylaxis in the United States under the product name ARAKODA. The safety of the approved regimen of tafenoquine for malaria prophylaxis has been assessed in five separate randomized, double-blind, active comparator or placebo-controlled trials for durations of up to six months. Tafenoquine has not been proven to be effective for treatment or prevention of babesiosis and is not approved by the FDA for such indications.